InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript

Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases May 8, 2026 8:30 AM EDTCompany ...

Why claim HIV is 'now curable' misrepresents research

Patients who have been "functionally cured" of HIV underwent incredibly risky procedures. For most people, though, HIV is no ...
University of California, Davis

Children with Rare, Debilitating Brain Diseases Suffer From Mutations in a Little-Known Protein Complex

Thousands of times per year, a family’s moment of joy turns to unexpected grief. A seemingly healthy infant stops smiling or ...

The unprecedented and deadly cruise ship hantavirus outbreak, explained

An unprecedented outbreak of hantavirus has rocked a luxury cruise ship off the coast of West Africa, triggering a tsunami of ...
MarketBeat on MSN

InflaRx investor update: Izicopan set to take center stage in AAV and renal disease pipeline

InflaRx (NASDAQ:IFRX) outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ...